cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome

in Endocrine Oncology
View More View Less
  • 1 L Gerard, Départment d’Oncologie Médicale, Hospices Civils de Lyon, Lyon, France
  • 2 D Barthelemy, CIRCAN (CIRculating CANcer) Platform, Hospices Civils de Lyon, Lyon, France
  • 3 A Gauthier, CIRCAN (CIRculating CANcer) Platform, Hospices Civils de Lyon, Lyon, France
  • 4 V Hervieu, Institut Multi-Site de Pathologie et Biologie Moléculaire, Hospices Civils de Lyon, Lyon, France
  • 5 J Lopez, Biochemistry, Hospital Lyon-Sud, University Lyon I, Pierre-Bénite, 69310, France
  • 6 B Gibert, INSERM, UMR 1052, Lyon Cancer Research Center, Université Lyon 1 Faculté de Médecine Laennec, Lyon cedex 08, France
  • 7 H Lasolle, Fédération d'Endocrinologie, Hospices Civils de Lyon, Lyon, France
  • 8 L Chardon, Biochimie, Centre Hospitalier Universitaire de Lyon, BRON, 69677 , France
  • 9 J Garcia, CIRCAN (CIRculating CANcer) Platform, Hospices Civils de Lyon, Lyon, France
  • 10 G Raverot, Fédération d'Endocrinologie, Hospices Civils de Lyon, Lyon, France
  • 11 L Payen, CIRCAN (CIRculating CANcer) Platform, Hospices Civils de Lyon, Lyon, France
  • 12 T Walter, Départment d’Oncologie Médicale, Hospices Civils de Lyon, Lyon, France

Correspondence: Laura Gerard, Email: laura_292@hotmail.fr

We report a case of metastatic pancreatic neuroendocrine carcinoma associated with paraneoplastic Cushing’s syndrome, successively treated with five lines of treatment (platin-etoposide, LV5FU2-dacarbazine, Folfirinox, pembrolizumab, and paclitaxel) and anti-secretory treatment. Circulating-free DNA (cfDNA) was analysed at each morphological evaluation starting from the second-line treatment. cfDNA changes were well-correlated with the disease course, and cfDNA may be used as a predictive marker and/or an early marker of response. In addition, absolute count of atypical cells was elevated upon disease progression.

 

Society for Endocrinology